Harmony Biosciences Q1 2024 Update
Ticker: HRMY · Form: 10-Q · Filed: 2024-04-30T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Harmony Biosciences Q1 2024 filing is out. Check financials and strategy.
AI Summary
Harmony Biosciences Holdings, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's filing details its financial performance and operational updates for the period. Specific financial figures and strategic developments are outlined within the report.
Why It Matters
This filing provides investors with the latest financial health and strategic direction of Harmony Biosciences, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Harmony Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-04-30 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Filer of the 10-Q report
- 20240331 (date) — End of the reporting period
- 20240430 (date) — Filing date of the report
FAQ
What is the primary business of Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on April 30, 2024.
What is the state of incorporation for Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc. is incorporated in Delaware (DE).
Does the filing mention any share repurchase programs?
Yes, the filing references the 'October2023ShareRepurchaseProgramMember' for the periods ending March 31, 2024, and March 31, 2023, as well as the periods from January 1, 2024, to March 31, 2024, and January 1, 2023, to March 31, 2023.
From the Filing
0001558370-24-006203.txt : 20240430 0001558370-24-006203.hdr.sgml : 20240430 20240430080035 ACCESSION NUMBER: 0001558370-24-006203 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24894089 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-Q 1 hrmy-20240331x10q.htm 10-Q http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember 0001802665 --12-31 Q1 false http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember 0 0 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P10Y 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-10-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-03-31 0001802665 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2024-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2024-03-31 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2023-03-31 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 srt:MinimumMember 2023-01-01 2023-12-31 0001802665 srt:MaximumMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-03-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001802665 country:US hrmy:WAKIXMember 2022-02-01 2022-02-28 0001802665 hrmy:TermLoanMember 2024-01-01 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001802665 hrmy:IncrementalTermLoanMember 2023-09-30 0001802665 hrmy:FiveYearSeni